Item request has been placed!
×
Item request cannot be made.
×
Processing Request
K2 Transfection System Boosts the Adenoviral Transduction of Murine Mesenchymal Stromal Cells.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
- Publication Information:
Original Publication: Basel, Switzerland : MDPI, [2000-
- Subject Terms:
- Abstract:
Adenoviral vectors are important vehicles for delivering therapeutic genes into mammalian cells. However, the yield of the adenoviral transduction of murine mesenchymal stromal cells (MSC) is low. Here, we aimed to improve the adenoviral transduction efficiency of bone marrow-derived MSC. Our data showed that among all the potential transduction boosters that we tested, the K2 Transfection System (K2TS) greatly increased the transduction efficiency. After optimization of both K2TS components, the yield of the adenoviral transduction increased from 18% to 96% for non-obese diabetic (NOD)-derived MSC, from 30% to 86% for C57BL/6-derived MSC, and from 0.6% to 63% for BALB/c-derived MSC, when 250 transduction units/cell were used. We found that MSC derived from these mouse strains expressed different levels of the coxsackievirus and adenovirus receptors (MSC from C57BL/6≥NOD>>>BALB/c). K2TS did not increase the level of the receptor expression, but desensitized the cells to foreign DNA and facilitated the virus entry into the cell. The expression of Stem cells antigen-1 (Sca-1) and 5'-nucleotidase (CD73) MSC markers, the adipogenic and osteogenic differentiation potential, and the immunosuppressive capacity were preserved after the adenoviral transduction of MSC in the presence of the K2TS. In conclusion, K2TS significantly enhanced the adenoviral transduction of MSC, without interfering with their main characteristics and properties.
- References:
Stem Cell Res Ther. 2017 Dec 22;8(1):288. (PMID: 29273086)
Int J Obes Relat Metab Disord. 2000 Nov;24 Suppl 4:S41-4. (PMID: 11126240)
Bone. 1992;13(1):81-8. (PMID: 1581112)
Exp Hematol. 2000 Apr;28(4):382-90. (PMID: 10781896)
Mol Biotechnol. 2000 Mar;14(3):197-203. (PMID: 10890010)
Exp Mol Med. 2009 May 31;41(5):315-24. (PMID: 19307751)
Eur J Immunol. 2009 Dec;39(12):3436-46. (PMID: 19798683)
Blood. 2005 Dec 15;106(13):4057-65. (PMID: 16118325)
Biotechnol J. 2015 May;10(5):741-7. (PMID: 25914340)
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14. (PMID: 9482916)
PLoS One. 2009 Sep 22;4(9):e7119. (PMID: 19771171)
Stem Cells. 2003;21(1):105-10. (PMID: 12529557)
Nat Rev Cancer. 2014 Oct;14(10):683-91. (PMID: 25176333)
Mol Ther. 2016 Feb;24(2):331-341. (PMID: 26478250)
Int J Mol Sci. 2020 Apr 26;21(9):. (PMID: 32357509)
Stem Cells Dev. 2011 Jul;20(7):1213-21. (PMID: 21067364)
Bone Res. 2016 Aug 09;4:16021. (PMID: 27547486)
Cell. 1993 Apr 23;73(2):309-19. (PMID: 8477447)
Blood. 2007 Nov 15;110(10):3499-506. (PMID: 17664353)
FASEB J. 2020 Nov;34(11):15236-15251. (PMID: 32959405)
BMC Cancer. 2014 Sep 25;14:713. (PMID: 25255777)
Trends Pharmacol Sci. 2020 Sep;41(9):653-664. (PMID: 32709406)
Tissue Eng. 2001 Apr;7(2):211-28. (PMID: 11304456)
World J Stem Cells. 2014 Nov 26;6(5):552-70. (PMID: 25426252)
Mol Ther. 2005 Aug;12(2):247-53. (PMID: 16043096)
Stem Cells Transl Med. 2012 Mar;1(3):200-5. (PMID: 23197779)
Mol Cells. 2017 Aug;40(8):598-605. (PMID: 28835020)
Gene Ther. 2003 May;10(10):928-31. (PMID: 12732877)
PLoS One. 2014 Mar 21;9(3):e92908. (PMID: 24658746)
Stem Cell Res Ther. 2020 Aug 8;11(1):345. (PMID: 32771052)
Stem Cells. 2004;22(7):1338-45. (PMID: 15579651)
J Membr Biol. 2018 Apr;251(2):179-185. (PMID: 28204840)
Blood. 2006 Sep 15;108(6):2114-20. (PMID: 16690970)
Science. 1997 Feb 28;275(5304):1320-3. (PMID: 9036860)
Stem Cell Rev Rep. 2012 Mar;8(1):243-50. (PMID: 21706142)
Int J Mol Sci. 2020 Aug 20;21(17):. (PMID: 32825521)
Blood. 2007 Jan 1;109(1):228-34. (PMID: 16985180)
Exp Hematol. 2002 Jan;30(1):42-8. (PMID: 11823036)
Science. 1999 Apr 2;284(5411):143-7. (PMID: 10102814)
J Cell Mol Med. 2012 Sep;16(9):2094-103. (PMID: 22151542)
Stem Cells Transl Med. 2015 Nov;4(11):1294-301. (PMID: 26400926)
Sci Rep. 2020 Mar 12;10(1):4593. (PMID: 32165680)
J Vis Exp. 2021 Jun 10;(172):. (PMID: 34180881)
Mol Reprod Dev. 2006 Nov;73(11):1393-403. (PMID: 16897738)
Methods. 2004 Jun;33(2):173-8. (PMID: 15121172)
Stem Cells Int. 2019 Jan 13;2019:9671206. (PMID: 30766609)
Stem Cells. 2009 Jun;27(6):1421-32. (PMID: 19489103)
Transplantation. 2003 Feb 15;75(3):389-97. (PMID: 12589164)
Biochem Biophys Res Commun. 2014 May 9;447(3):383-7. (PMID: 24727452)
J Immunol. 2009 Jul 15;183(2):993-1004. (PMID: 19561093)
Hum Gene Ther. 1998 Nov 20;9(17):2493-502. (PMID: 9853516)
World J Stem Cells. 2014 Nov 26;6(5):526-39. (PMID: 25426250)
Front Immunol. 2019 Jun 04;10:1191. (PMID: 31214172)
Mol Ther. 2000 Jan;1(1):39-48. (PMID: 10933910)
Stem Cell Res Ther. 2019 Jan 11;10(1):18. (PMID: 30635041)
- Grant Information:
POC-A.1-A.1.1.4-E-2015, ID: P_37_668 European Regional Development Fund; PN-III-P2-2.1-PED-2019-4574 CCCDI - UEFISCDI
- Contributed Indexing:
Keywords: BALC/c-derived MSC; C57BL/6-derived MSC; K2 transfection system; NOD-derived MSC; adenovirus; mesenchymal stromal cells; transduction
- Accession Number:
0 (Receptors, Virus)
- Publication Date:
Date Created: 20210113 Date Completed: 20210907 Latest Revision: 20240330
- Publication Date:
20240330
- Accession Number:
PMC7826527
- Accession Number:
10.3390/ijms22020598
- Accession Number:
33435318
No Comments.